Yellow fever vaccine viremia following ablative BM suppression in AML

Univ São Paulo, Sch Med, Dept Infect & Parasit Dis, São Paulo, BrazilHosp Sirio Libanes, São Paulo, BrazilUniv São Paulo, Sch Med, Div Clin Immunol & Allergy, São Paulo, BrazilFundacao Prosangue Hemoctr São Paulo, São Paulo, BrazilUniversidade Federal de São Paulo, Infect Dis Div DIPA, São Paulo, BrazilFundacao Oswaldo Cruz, Rio de Janeiro, BrazilUniversidade Federal de São Paulo, Infect Dis Div DIPA, São Paulo, BrazilWeb of Scienc

Patient's dissatisfaction with the public and private laboratory services in conducting HIV related testing in Tanzania

<p>Abstract</p> <p>Background</p> <p>Patient's satisfaction with both private and public laboratory services is important for the improvement of the health care delivery in any country.</p> <p>Methods</p> <p>A cross-sectional survey was conducted in 24 randomly selected health facilities with laboratories that are conducting HIV related testing, in Mainland Tanzania. The study assessed patient's satisfaction with the laboratory services where by a total of 295 patients were interviewed.</p> <p>Results</p> <p>Of data analyzed for a varying totals from 224 to 294 patients, the percentage of dissatisfaction with both public and private laboratory services, ranged from 4.3% to 34.8%, with most of variables being more than 15%. Patients who sought private laboratory services were less dissatisfied with the cleanness (3/72, 4.2%) and the privacy (10/72, 13.9%) than those sought public laboratory service for the same services of cleanness (41/222, 18.5%) and privacy (61/222, 27.5%), and proportional differences were statistically significant (X²= 8.7, p = 0.003 and X²= 5.5, p = 0.01, respectively). Patients with higher education were more likely to be dissatisfied with privacy (OR = 1.8, 95% CI: 1.1–3.1) and waiting time (OR = 2.5, 95% CI: 1.5 – 4.2) in both private and public facilities. Patients with secondary education were more likely to be dissatisfied with the waiting time (OR = 5.2; 95%CI: 2.2–12.2) and result notification (OR = 5.1 95%CI (2.2–12.2) than those with lower education.</p> <p>Conclusion</p> <p>About 15.0% to 34.8% of patients were not satisfied with waiting time, privacy, results notification cleanness and timely instructions. Patients visited private facilities were less dissatisfied with cleanness and privacy of laboratory services than those visited public facilities. Patients with higher education were more likely to be dissatisfied with privacy and waiting time in both private and public facilities.</p

EFEITOS DA MAMOPLASTIA REDUTORA NA FUNÇÃO PULMONAR E QUALIDADE DE VIDA DE MULHERES SUBMETIDAS À GIGANTOPLASTIA

Objective: To evaluate the effects of reduction mammoplasty on the pulmonary function andquality of life of women with gigantomastia.Method: Observational study (a case series) that retrospectively analyzed the medical recordsof 14 cases of women who underwent reduction mammoplasty in the last 12 months at thesurgical clinic service of a university hospital in Rio de Janeiro.Results: The mean age, height and weight of the women who underwent mammoplastywere, respectively, 44.5 years, 158 cm and 93.8 kg. Body mass index revealed obesity classesranging from I to III. Regarding spirometry, the values of FVC ranged from 92.76% of thepredicted theoretical value before surgery to 94.74% and 91.77%, respectively 30 and 60 daysafter surgery.Conclusion: Reduction mammoplasty can improve women’s quality of life, according to thereports of the participants. There was no association between mammoplasty and improvementof the respiratory function.Objetivo: avaliar os efeitos da mamoplastia redutora na função pulmonar e qualidade de vida demulheres com gigantomastia.Método: estudo observacional do tipo série de casos que analisou retrospectivamente o prontuáriode 14 casos de mulheres submetidas à mamoplastia redutora nos últimos 12 meses no serviço declínica cirúrgica de um hospital universitário do Rio de Janeiro.Resultados: a média de idade, altura e peso das mulheres submetidas à mamoplastia foirespectivamente, 44,5 anos, 1,58 m e 93,8 kg. O índice de massa corporal evidenciou obesidadede graus I a III. Em média a espirometria variou de 92,76% do valor teórico predito antes da cirurgia,para 94,74% e 91,77%, 30 e 60 dias após a cirurgia respectivamente.Conclusão: a mamoplastia de redução pode melhorar a qualidade de vida das mulheres, conformeautorrelato. Não houve associação da mamoplastia com a melhora da função respiratória.Objetivo: Evaluar efectos de la mamoplastía reductora en función pulmonar y calidad de vidade mujeres con gigantomastía.Método: Estudio observacional tipo serie de casos, con análisis retrospectivo de historiasclínicas de 14 casos de mujeres sometidas a mamoplastía reductora en los últimos 12 mesesen servicio de cirugía clínica de hospital universitario de Rio de Janeiro.Resultados: La media etaria, altura y peso de las mujeres sometidas a mamoplastía fue,respectivamente: 44,5 años, 1,58 m y 93,8 kg. El índice de masa corporal evidenció obesidadde grados I a III. En promedio, la espirometría varió del 93,76% del valor teórico previstoantes de la cirugía al 94,74% a los 30 días de la cirugía y 91,77% a los 60.Conclusión: La mamoplastía reductora puede mejorar la calidad de vida de las mujeres, segúnsu testimonio. No existió asociación de la mamoplastía con mejoras en la función respiratoria

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2–4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease